Comparison of Clinical Effects between Percutaneous Transluminal Septal Myocardial Ablation and Modified Morrow Septal Myectomy on Patients with Hypertrophic Cardiomyopathy
机构:[1]Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China临床科室心脏外科中心首都医科大学附属安贞医院[2]Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China临床科室心脏内科中心首都医科大学附属安贞医院
Background:Percutaneous transluminal septal myocardial ablation (PTSMA) and modified Morrow septal myectomy (MMSM) are two invasive strategies used to relieve obstruction in patients with hypertrophic cardiomyopathy (HCM).This study aimed to determine the clinical outcome of these two strategies.Methods:From January 2011 to January 2015,226 patients with HCM were treated,68 by PTSMA and 158 by MMSM.Both ultrasonic cardiograms and heart functional class were recorded before,after operations and in the follow-up.Categorical variables were compared using Chi-square or Fisher's exact tests.Quantitative variables were compared using the paired samples t-test.Results:Interventricular septal thickness was significantly reduced in both groups (21.27 ± 4.43 mm vs.18.72 ± 4.13 mm for PTSMA,t =3.469,P < 0.001,and 21.83 ± 5.03 mm vs.16.57 ± 3.95 mm for MMSM,t =10.349,P < 0.001,respectively).The left ventricular outflow tract (LVOT) pressure gradient (PG) significantly decreased after the operations in two groups (70.30 ± 44.79 mmHg vs.39.78 ± 22.07 mmHg for PTSMA,t =5.041,P < 0.001,and 74.58 ± 45.52 mmHg vs.13.95 ± 9.94 mmHg for MMSM,t =16.357,P < 0.001,respectively).Seven patients (10.29%) in the PTSMA group required a repeat operation in the follow-up.Eight (11.76%)patients were evaluated for New York Heart Association (NYHA) Ⅲ/Ⅳ in the PTSMA group,which was significantly more than the five (3.16%) in the same NYHA classes for the MMSM group at follow-up.Less than 15% of patients in the PTSMA group and none of the patients in the MMSM group complained of chest pain during follow-up.Conclusions:Both strategies can not only relieve LVOT PG but also improve heart function in patients with HCM.However,MMSM might provide a more reliable reduction in gradients compared to PTSMA.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81370328, 81770371]
第一作者机构:[1]Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
通讯作者:
通讯机构:[1]Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China[*1]Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Street, Beijing 100029, China
推荐引用方式(GB/T 7714):
Guo Hong-Chang,Li Jin-Hua,Jiang Teng-Yong,et al.Comparison of Clinical Effects between Percutaneous Transluminal Septal Myocardial Ablation and Modified Morrow Septal Myectomy on Patients with Hypertrophic Cardiomyopathy[J].Chinese Medical Journal.2018,131(5):527-531.doi:10.4103/0366-6999.226075.
APA:
Guo, Hong-Chang,Li, Jin-Hua,Jiang, Teng-Yong,Ren, Chang-Wei,Dai, Jiang...&Lai, Yong-Qiang.(2018).Comparison of Clinical Effects between Percutaneous Transluminal Septal Myocardial Ablation and Modified Morrow Septal Myectomy on Patients with Hypertrophic Cardiomyopathy.Chinese Medical Journal,131,(5)
MLA:
Guo, Hong-Chang,et al."Comparison of Clinical Effects between Percutaneous Transluminal Septal Myocardial Ablation and Modified Morrow Septal Myectomy on Patients with Hypertrophic Cardiomyopathy".Chinese Medical Journal 131..5(2018):527-531